FSD Pharma Inc. Securityholders Approve Plan of Arrangement with Celly Nutrition Corp.
TORONTO, ON / ACCESSWIRE / November 21, 2023 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical...
Brain
NeuroPace to Present at the Piper Sandler 35th Annual Healthcare Conference
MOUNTAIN VIEW, Calif., Nov. 21, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on...
IRLAB to present at SEB Annual Healthcare Seminar on November 23, 2023
GOTHENBURG, SE / ACCESSWIRE / November 21, 2023 / IRLAB Therapeutics (STO:IRLAB-A) (FRA:6IRA) Gothenburg, Sweden, November 21, 2023 - IRLAB...
Hyperfine, Inc. Announces Presentations on Clinical Advancements at RSNA 2023
Innovative approaches in MRI technology demonstrate the potential of portable ultra-low-field brain imaging to assist in improving brain healthGUILFORD, Conn.--(BUSINESS...
Anavex Initiates Regulatory Submission of Oral Blarcamesine for Alzheimer’s Disease to European Medicines Agency (EMA)
NEW YORK, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage...
Louisiana Insurer Expands Deep TMS™ Access for 1.9 Million Covered Lives
BURLINGTON, Mass. and JERUSALEM, Nov. 20, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”),...
Zevra Therapeutics Completes Acquisition of Acer Therapeutics in its Journey to Become a Leading Rare Disease Company
Acquisition includes OLPRUVA®, an FDA-approved treatment for urea cycle disorders (UCDs), which propels Zevra into commercial stage, diversifying its revenue...
Plus Therapeutics Reports New Interim ReSPECT-GBM Phase 2 Trial Data at the Society for NeuroOncology Annual Meeting and will Host Key Opinion Leader Webinar
Median overall survival (mOS) in 15 patients with recurrent glioblastoma (rGBM) from the Phase 2 study is 13 months, which...
Enterome’s OncoMimics™ Immunotherapy EO2401 Significantly Improves Survival Rate in Recurrent Glioblastoma
Positive data from the ROSALIE Phase 1/2 trial presented at 2023 SNO Annual Meeting Median survival of 14.5 months and...
Nexstim Receives NBS System 6 Order from Hospital in United States
Press release, Helsinki, 20 November 2023 at 11 AM (EET) Nexstim Receives NBS System 6 Order from Hospital in United...
MediciNova Announces New Data and Results of a Phase 2 Clinical Trial of MN-166 (ibudilast) in Glioblastoma Presented at the 28th Annual Meeting of the Society for Neuro-Oncology
LA JOLLA, Calif., Nov. 19, 2023 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market...
IRLAB to present at Redeye Life Science Day on November 23, 2023
GOTHENBURG, SE / ACCESSWIRE / November 20, 2023 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, November 20, 2023 - IRLAB Therapeutics...
IRLAB to Present at ABGSC Investor Days on November 22, 2023
GOTHENBURG, SE / ACCESSWIRE / November 20, 2023 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, November 20, 2023 - IRLAB Therapeutics...
Masimo W1™ Medical Watch Receives FDA 510(k) Clearance for Over-the-Counter and Prescription Use
IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) today announced that the Masimo W1™ medical watch has received FDA 510(k) clearance for over-the-counter...
FSD Pharma Announces Distribution Date for Distribution of Celly Shares Pursuant to Plan of Arrangement
TORONTO, ON / ACCESSWIRE / November 17, 2023 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical...
Medicenna Announces Compelling Survival Benefit from Phase 2b Study of Bizaxofusp in Recurrent Glioblastoma at the 28th Annual Meeting of the Society for NeuroOncology
Single treatment of bizaxofusp doubled mOS (14.5 months vs. 7.2 months) irrespective of IL4R expression (high or low) compared to...
Day One Announces Tovorafenib FIREFLY-1 Data Published in Nature Medicine
Data subsets to be shared today in plenary oral presentations at the 2023 Society for Neuro-Oncology Annual MeetingBRISBANE, Calif., Nov....
Alpha Tau Medical Announces Third Quarter 2023 Financial Results and Provides Corporate Update
- Treated the first patient with advanced inoperable pancreatic cancer at Hadassah Medical Center in Israel in September, alongside safety...
Hyperfine, Inc. to Present at the Piper Sandler 35th Annual Healthcare Conference
GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking medical device company that has redefined brain imaging with the world’s first...
Odyssey Health, Inc, Selects Syneos Health to Support Investigational New Drug Application for Treatment of Concussion
LAS VEGAS, NV / ACCESSWIRE / November 16, 2023 / Odyssey Health, Inc. (OTCQB:ODYY), f/k/a Odyssey Group International, Inc., a...